Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $31.1M | $17.8M | $29.8M | $38.6M | $77.0M | $54.5M | $84.0M |
| Revenue growth | — | -42.7% | 66.9% | 29.8% | 99.3% | -29.1% | 54.0% |
| Operating income | -$22.2M | -$65.0M | -$118M | -$184M | -$155M | -$213M | -$286M |
| Operating margin | -71.5% | -364.7% | -396.3% | -476.0% | -201.4% | -390.5% | -340.2% |
| Net income | -$21.7M | -$43.2M | -$117M | -$180M | -$144M | -$194M | -$264M |
| Net margin | -69.7% | -242.7% | -393.9% | -466.9% | -187.0% | -354.9% | -314.9% |
| EPS (diluted) | -$6.59 | -$2.76 | -$2.73 | -$3.71 | -$2.65 | -$2.88 | -$3.05 |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | $601K | -$80.0K | -$84.4M | -$160M | -$81.4M | -$173M | -$249M |
| Capital expenditures | $1.65M | $4.55M | $5.66M | $12.2M | $8.40M | $9.27M | $14.0M |
| Free cash flow | -$1.05M | -$4.63M | -$90.0M | -$172M | -$89.8M | -$182M | -$263M |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $34.8M | $119M | $80.5M | $64.5M | $54.6M | $110M | $247M |
| Total assets | $44.0M | $396M | $477M | $417M | $356M | $669M | $688M |
| Total liabilities | $53.6M | $106M | $134M | $113M | $155M | $142M | $149M |
| Shareholders' equity | -$57.7M | $290M | $342M | $304M | $200M | $527M | $539M |
| Retained earnings | -$60.5M | -$104M | -$221M | -$401M | -$545M | -$739M | -$1.00B |
| Shares (wtd avg diluted) | 3.60M | 38.9M | 42.9M | 48.6M | 54.3M | 67.1M | 86.7M |
Every figure is extracted from Nurix Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.